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EA
D
S
C
O
g
o
p
T
e
r
6
r
S
o
b
t
d
d
f
r
r
o
t
p
C
s
a
i
h
i
t
c
3
s
l
t
a
i
i
E
a
i
p
p
t
r
i
e
b
t
P
fl
m
s
p
f
t
t
L
o
s
t
p
t
i
c
e
i
t
t
c
s
3
“
p
c
r
r
s
l
X
s
t
m
c
*
a
t
C
a
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 2 , N O . 1 0 , 2 0 0 9
© 2 0 0 9 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / 0 9 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 0 9 . 0 6 . 0 1 7DITORIAL COMMENT
Generation 2.5
rug-Eluting Stent?*
tephen G. Ellis, MD
leveland, Ohio
ne might easily ask: “Do we really need another second-
eneration limus-eluting stent?”
To answer this question, one has to look at the limitations
f first-generation drug-eluting stents (DES) and the im-
rovements demonstrated with second-generation DES.
he initial Cypher and Taxus products are remarkably
ffective in reducing the previous “Achilles’ heel” of stents—
estenosis—although they are not perfect. For example, the
-year freedom from target lesion revascularization recently
eported for Cypher from the SIRIUS (Sirolimus-Eluting
tent in De Novo Native Coronary Lesions) trial was just
ver 10%, a 50% relative reduction compared with the
are-metal stent. Similar data at 5 years are available with
he Taxus stent from the Taxus IV study. Admittedly,
ifferences in revascularization are exaggerated somewhat
See page 977
ue to early mandatory angiographic follow-up, and results
or both stents are from a relatively low-risk population,
eflecting 30% to 40% of stent usage today. Restenosis rates
ise as lesion complexity increases. The principal limitation
f these stents is the associated risk of stent thrombosis—
he new “Achilles’ heel” of stents. In the low-risk patient
opulations noted earlier, the risk of Academic Research
onsortium–defined definite plus probable stent thrombo-
is is approximately 1% in the first year, with a continued
pproximate 0.3%/year risk through at least year 4 to 5, but
n certain patient populations it might be considerably
igher (e.g., 3% in the first year for ST-segment myocardial
nfarction [1], or 0.4% to 0.6%/year continuing at least
hrough 5 years the Bern/Rotterdam experience [2] in
omplex patients). Such stent thrombosis is fatal in 20% to
0% of patients and, when nonfatal, usually results in a
ubstantial myocardial infarction. Stent thrombosis has been
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nd Abbott Vascular.inked to a variety of factors, some that relate to procedural
echnique (stent under expansion) or patient characteristics
nd others that are linked to delayed endothelial healing and
nflammation resulting from the anti-restenosis agent and
ts accompanying polymer.
Current (U.S.) second-generation stents are the Medtronic
ndeavor, Abbott/Boston Scientific Xience V/Promus,
nd Taxus Liberte stents. The Medtronic Endeavor stent
s unique in that it uses the nondurable rapid release
hosphorylcholine/2-methacryloyloxethylpolymer phos-
horylcholine polymer combination in conjunction with
he antiproliferative agent zotarolimus. Likely due to the
elatively brisk release of the active agent, this stent is
ntermediate between bare metal stents and other limus-
luting stents in terms of its capacity to reduce restenosis
ut at the same time seems likely to have less risk of stent
hrombosis after the first 9 to 12 months. The Xience/
romus stent uses the durable polymer poly-vinylidene
uoride-hexafluoropropylene in conjunction with its li-
us agent, everolimus. Restenosis rates with this stent
eem quite similar to that of the “gold standard” Cypher
roduct, as does risk of stent thrombosis, although data
rom the truly large number of patients required to reduce
he uncertainty about the point estimate of risk of stent
hrombosis for this product do not yet exist. The Taxus
iberte stent is a relatively minor modification of the
riginal Taxus Express stent, with a more closely knit
tent structure leading to a more homogenous distribu-
ion of drug. This stent uses the durable polymer SIBS,
olystyrene-b-isobutylene-b-styrene, in conjunction with
he unique antiproliferative drug paclitaxel. This seems to
mprove target lesion revascularization in small vessels
ompared with the original Taxus stent. Long-term
stimates of risk of stent thrombosis are not available, but
t would seem unlikely that they differ substantially from
he original Taxus stent. Some investigators have pointed
o an apparent difference in rates of target lesion revas-
ularization after 1 year in pivotal trials with somewhat
imilar patient populations (Endeavor 1.3%, Cypher
.0%, Taxus 3.4% through 4 years), postulating chronic
irritation” from residual polymer and/or drug, but com-
arisons such as this are somewhat challenging because of
hanging concomitant drug use and lack of head-to-head
andomized comparison. In addition to their anti-
estenosis effects noted in the preceding text, all of these
econd-generation stents provide somewhat greater de-
iverability than either of the first-generation stents, and
ience V/Promus and TAXUS Liberte probably have
imilar safety to first-generation DES. True demonstra-
ion that Endeavor has a lesser risk of stent thrombosis
ust await the results of the large PROTECT study
omparing the Endeavor and Cypher products (2-year
ata will not be available until early 2011).
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987From a biologic standpoint, the Endeavor Resolute stent
iffers from the original Endeavor stent due only to its
olymer and from other second-generation stents by virtue
f its antiproliferative agent and its polymer. It is simplistic
o think that all limus agents are the same—certainly they
iffer with regard to relative impact on the mammalian
arget of rapamycin (mTOR) antiproliferative and cal-
ineurin pathways and lipophilicity, amongst other at-
ributes. Compared with sirolimus, zotarolimus has compa-
able binding to FKBP12 (a prelude to binding mTOR)
nd, on a nanomolar basis, has somewhat less inhibition of
mooth muscle proliferation and greater inhibition of con-
anavalin A-induced T cell proliferation and mixed lym-
hocyte response inhibition (3). At the doses used in the
ypher and Endeavor Resolute stents, both drugs are
robably on the flat portion of their dose response curves
ith regard to smooth muscle cell/neointimal proliferation
nhibition during the first few weeks after stent implanta-
ion. These agents also delay endothelial healing after DES
lacement, probably to a similar degree. It has been postu-
ated that the carrier polymer on DES is at least partially
esponsible for the chronic inflammatory response that is
ometimes seen (4). This has been attributed, with some
onjecture, to the presence of irritants (solvents, residual
onomers), hydrophobic/hydrophilic properties, and deg-
adation products. The Endeavor Resolute polymer is a
lend of 3 polymers, C19 (a mixture of hexyl methacrylate,
inyl pyrrolidone and vinyl acetate), C10 (primarily
utylmethacrylate), and polyvinyl pyrrolldinone, which
elease one-half of their zotarolimus load over the 10 to
4 days and the remainder more gradually over 8 to 10
eeks (5). Bench testing in comparison with the poly-
butyl methacrylate) (Cypher cap coat polymer), SIBS
Taxus), and VFH-Fluoropolymer (Xience V/Promus)
olymers finds this polymer to be associated with less
onocyte adhesion and less tissue factor and protease-
ctivated receptor-2 expression (6). This has been attrib-
ted, at least in part, to the contribution of the outer
urface hydrophilic C19 polymer (the other polymers are
ydrophobic) (7).
In this first reported experience, 139 patients with
elatively simple lesions (de novo, diameter 2.5 to 3.5
m, length 14 to 27 mm) were treated with the Endeavor
esolute stent and evaluated with the primary study end
oint of 9-month in-stent late loss (8). Recent myocar-
ial infarction was an exclusion criterion, and diabetic
ubjects were infrequent. The 12-month clinical out-
omes were also tracked. Mean late loss was 0.22 mm,
nd the important right side of the Gaussian distribution
f late loss that drives target vessel revascularization was
ot described. One possible late stent thrombosis (9
onths) occurred.
What, ideally, is needed now? Although it might benderstandable that the Food and Drug Administration
3equired initial DES trials to test safety and efficacy in
ow-risk patients, to continue to limit DES studies to a
roup of patients making up the minority of those
ndergoing percutaneous coronary intervention today
oes a tremendous disservice to the interventional com-
unity. They should give up the idea that a new DES
ust be tested within the confines of approved indica-
ions, when such patients make up only one-third or so of
ll patients treated and others have been well-studied in
egistries. A head-to-head study with Endeavor Resolute
nd any of a number of comparators (Cypher, Xience
/Promus, or even the original Endeavor Stent) in an
ll-comer’s population in a study of sufficient size to
scertain relative benefit with follow-up long enough to
udge efficacy and get an initial read on safety would be
remendously helpful. A registry study compared results
ith previous trial data might be sufficient when there are
nly minor changes in the configuration of a stent (e.g.,
axus Express and Taxus Liberte), but suffers from the
eakness of not being able to adjust for changes in
echnique or concomitant medications (e.g., more intra-
ascular ultrasound or new thienopyridine usage). Ascer-
aining differences in low-frequency events such as stent
hrombosis is much more difficult. Approximately 8,000
atients total are required for an 80% power, assuming
tent A has a thrombosis risk of 2% and stent B has a risk
f 3%. Adequate post-provisional approval surveillance
ould likely be a more reasonable approach, providing
hat basics such as consecutive patient enrollment, com-
lete follow-up, adequate auditing (the same or nearly
he same as that done for pivotal randomized trials), and
ollow-up (at least 3 years, preferably 5 years) were
ollowed. Only then will we know whether or not this stent
s really generation 2.5.
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